Release date: 2026-01-05 14:04:26 Recommended: 104
It is indicated for the treatment of relapsed or refractory acute leukemia (with KMT2A translocation) or relapsed or refractory acute myeloid leukemia (with NPM1 mutation) in adult patients and pediat